 |
|
Mild Guillain-Barré Syndrome
Deborah M. Green, MD;
Allan H. Ropper, MD
Arch Neurol. 2001;58:1098-1101.
ABSTRACT
| |
Background The unpredictability of the early course of Guillain-Barré syndrome
(GBS) makes it difficult to determine which patients' conditions will worsen
under observation. Most large randomized treatment trials for GBS have used
an inability to walk as the enrollment criterion. Consequently, little is
known about the treatment of those patients with milder degrees of affection.
Objectives To determine the approximate frequency of mild GBS with the persistent
ability to walk and to see if there were features that predicted that the
illness would remain mild.
Setting A registry of patients with GBS seen on the wards and in the neurology
clinic from January 1,1992, to May 1, 2000, in a 400-bed community teaching
hospital.
Patients Twelve (4.7%) of 254 patients in our case series were able to walk throughout
their illness. Eight had been treated with plasmapheresis or intravenous immunoglobulin;
the others were observed without treatment.
Results There was no age, sex, or seasonal preponderance in comparison with
large case series that included cases of all severities. Nine of 12 patients
had a preceding respiratory tract infection, 10 had paresthesias, 7 had prominent
pain, and 9 had ataxia. Seven of 10 patients who were examined had normal
cerebrospinal fluid protein levels. It took 8 days, on average, to reach the
maximal degree of weakness. One additional treated patient, excluded from
our case series, had mild weakness for the first 3 weeks and subsequently
worsened with a relapsing course more typical of chronic inflammatory demyelinating
polyneuropathy. Eleven patients demonstrated proximal, intermediate, or distal
conduction block, and only 3 had a mild degree of denervation. There were
no distinguishing clinical or electrophysiologic features between treated
and untreated patients with mild GBS and, except for the mild degree of affection
and the absence of substantial electromyographic changes of axonal disruption,
there were no important differences between these mild cases as a group and
patients who developed more severe GBS.
Conclusions Cases of mild GBS reach a clinical nadir in a similar time to those
with more severe disease. Treatment may be unnecessary in patients who are
able to walk during the second week of illness, but observation until approximately
the eighth day seems appropriate to be certain that the illness does not progress.
In all likelihood there are mild cases of GBS that never come to the attention
of a neurologist.
INTRODUCTION
GUILLAIN-BARRÉ syndrome (GBS) is generally easy to identify by
its typical clinical features and by the progression of weakness over several
days. In most large randomized trials that have established the effectiveness
of immune treatments for GBS, the enrollment criterion has been the patient's
inability to walk (Medical Research Council grade 3 or higher).1
The problem often arises regarding treatment for a patient with GBS who has
not reached this threshold; for example, one who is still able to walk without
assistance. Little is written about this group of patients and the unpredictability
of the early clinical course of GBS makes it difficult to judge which patient's
condition will worsen under observation. We determined the approximate frequency
of this type of mild GBS, looked for features that predicted the persistence
of this lesser degree of affection, and considered whether treatment might
be avoided in these individuals.
PATIENTS AND METHODS
Cases of mild GBS seen on the wards and in the neurology clinic from
January 1, 1992, to May 1, 2000, were selected from the registry of St Elizabeth's
Medical Center, Boston, Mass. Patients were chosen if they were able to walk
without assistance (Medical Research Council grades 1 or 2) until they began
to improve.1 They otherwise had the typical
features of bilateral limb weakness, distal paresthesias, mild sensory changes,
some with, and others without, cranial nerve weakness. Patients with variants
of GBS such as Fisher syndrome, pure or predominantly cranial nerve involvement,
or purely sensory impairment were not considered. One patient with chronic
inflammatory demyelinating polyneuropathy that became apparent later is considered
separately. Each patient underwent electromyography (EMG); all but 2 had cerebrospinal
fluid (CSF) studies performed at the early stage of the illness.
To summarize the extent of weakness, a motor scale was devised by adding
the sum of 4 measurements of power derived from the proximal and distal parts
of all 4 limbs on the Medical Research Council muscle power grading scale
(each measurement ranging from 0, no movement, to 5, normal power). The summed
motor score constituted a total of the following 4 averaged strength measurements:
both arms proximally (deltoid, biceps, and triceps), both arms distally (wrist
extensors and interossei), both legs proximally (iliopsoas, quadriceps, and
hamstrings), and both legs distally (tibialis anterior and gastrocnemius).
A normal motor examination resulted in a score of 20. We also recorded the
average vital capacity for each day or the single measurement for the day.
RESULTS
Twelve (4.7%) of the 254 patients examined during the study period were
able to walk throughout their entire course of GBS. A typical example was
a 52-year-old man (patient 3) with an upper respiratory tract illness who,
2 weeks later, developed lower back pain and paresthesias in the hands and
feet. Four days later he had diplopia and difficulty walking. Six days after
onset he was at his weakest with a unilateral abducens palsy, mild symmetric
proximal more than distal weakness in the arms and legs, universal areflexia,
diminished vibration sensation at the toes, and a wide-based gait. The lowest
vital capacity during his hospital course was 3.1 L. On the second day of
illness, the CSF protein level was 490 g/L (49 mg/dL) and the nerve conduction
studies showed proximal motor nerve conduction block, and absent or reduced
sensory nerve action potentials. The needle EMG demonstrated no denervation.
He completed a course of intravenous immunoglobulin and was given intravenous
steroids for diffuse pains in the lower back, neck, shoulders, and hands.
His strength was nearly normal after 3 weeks, he returned to work by 2
months, but still had dysesthesias of his hands.
One additional patient appeared to have a mild form of GBS over 3 weeks
but worsened 2 months later, requiring a wheelchair. She was believed to have
chronic inflammatory demyelinating polyneuropathy based on later relapses
and was excluded from this case series.
The clinical characteristics of the 12 patients with mild GBS, including
the lowest motor score and the lowest vital capacity, are given in Table 1. Their ages ranged from 19 to 64
years. Nine patients had a preceding upper respiratory tract infection, but
they did not cluster at any particular time of the year. All but 2 had paresthesias.
Pain was a significant feature in 7 patients; 2 had lower back pain, but others
reported periarticular pain or more diffuse pain involving not only the lower
back, but also the neck, shoulders, hands, and calves. One patient developed
proximal and distal dysesthesias in all 4 limbs. Another patient continued
to have substantial pain even 6 months after the onset of the illness. Thse
were lancinating pains that initially involved the proximal upper extremities
but during the next 2 weeks became situated primarily in the patient's hands
and were severe enough to require the administration of pain medications and
epidural steroid injections.
|
|
|
|
Table 1. Clinical Characteristics of Patients With Persistently Mild
Guillain-Barré Syndrome*
|
|
|
The worst motor scores ranged from 14 to 19 (20 being full strength)
and remained essentially unchanged or improved mildly during observation.
Maximal weakness occurred within 1 week in 7 patients and within 14 days in
all patients; the average time to nadir was 8 days. All were areflexic or
had a few trace reflexes present. All but 3 had some degree of ataxic gait,
generally minimal. Four of the 12 patients had cranial nerve palsies, mostly
facial. None had bladder or autonomic involvement. The vital capacity was
above 1.74 L in all patients, most exceeding 2.4 L. These measurements were
stable during the hospital course. The CSF protein level was elevated in only
3 of the 10 patients in whom it was measured, but in some instances the normal
protein level may have been related to the brief duration of illness at the
time of sampling.
All of the patients had an EMG between the 2nd and 21st day of illness.
Only the first EMG results are listed in Table 2, although 2 patients had subsequent studies. All findings
were abnormal, demonstrating demyelination, with additional axonal involvement
in 3 patients. Nerve conduction study findings were abnormal, ie, slowing
or block, in more than 1 nerve in all but 2 studies. Proximal conduction block,
defined as the absence of an F wave or prolonged F-wave latency (adjusted
for height) that was not explained by distal dispersion or slowing, was present
in 8 patients. Distal block, defined as a greatly prolonged distal latency,
was found in numerous nerves in 7 patients. Conduction block along the course
of a nerve, excluding a proximal or distal block in the same nerve, was demonstrated
in 6 patients. Slowing of nerve conduction velocities was present in 6 patients.
Reduction in compound muscle action potential amplitudes, not meeting criteria
for conduction block, was present in 3 patients and suggested axonal involvement.
Sensory nerve action potentials were absent or were reduced in amplitude in
4 patients and, in another, there was a prolonged distal latency. Only 3 of
the patients had denervation changes (fibrillations or positive sharp waves)
on needle EMG; these studies were performed later in the course of illness
(14-21 days).
|
|
|
|
Table 2. Electromyographic Results of Patients With Persistently Mild
Guillain-Barré Syndrome (GBS)*
|
|
|
Six of the patients were available for reevaluation 2 months or longer
after the onset of their illness (Table
1). All had normal or near-normal neurologic examination results
at that time and those who were employed previously returned to work in 2
to 6 months. Two patients still had sensory symptoms at 6 months, 1 with dysesthesias
in the hands and 1 with paresthesias of the hands and feet. There was no apparent
difference in the speed of recovery or the residual symptoms between the 8
patients treated with intravenous immunoglobulin or plasmapheresis compared
with the 4 who were untreated.
COMMENT
In all likelihood there are mild cases of GBS that never come to the
attention of a neurologist. In our series, 4.7% of the patients had persistently
mild weakness and were able to walk throughout their illness. This compares
with 28% in a study from the Netherlands,2
9% in our previous prospective series of 120 patients with GBS,3
9% in the French Cooperative Group on Plasma Exchange in Guillain-Barré
Syndrome series of 556 patients,4 and 12% of
100 patients with GBS in the prospective series of Winer et al.5
The mild cases that came to our attention showed no age or sex preponderance
and no seasonal grouping, in contrast with some of the findings in the recent
Netherlands survey.2 In keeping with the stereotypic
syndrome of GBS, most of our patients had a preceding infection, all but 2
had paresthesias, many had significant pain of several varieties, but none
had autonomic involvement. The significant pain syndrome in most of these
patients that was disproportionate to the mild motor involvement was somewhat
surprising. The average time to reach a clinical nadir in terms of power was
8 days, and in all cases occurred within 14 days. Most patients had a normal
or near-normal CSF protein level and none had electrophysiologic evidence
of denervation within 13 days of the onset of weakness. There was no particular
pattern of EMG changes that characterized this group except perhaps the absence
of substantial axonal findings. The CSF studies and EMG were performed during
the early stage of the illness and may have underestimated the peak CSF protein
level and the amount of axonal degeneration.
We were unable to determine how many patients with GBS who had mild
illness at 8 days, later had a deterioration of their condition, but our impression
from the remainder of our case series is that very few cases fell into this
category. This average interval of 8 days to reach a nadir was similar to
the findings of other studies that included large numbers of patients with
GBS of all grades of severity, including our own.3
For example, the nadir was reached within 7 days in 34% (14 days in 70%) of
the patients described by Winer et al,5 within
7 days in 74% of the patients described by Marshall,6
and 12 days was the average in both case series reported by Ravn7
and Loffel et al.8 Similarly, experience in
a retrospective group of 169 patients found that 38% reached nadir by 7 days
and 77% within 14 days.3 Furthermore, it has
been our experience and that of others that transient improvement in power
or paresthesias followed by worsening does not occur except in relation to
immune treatment, ie, a rebound. This type of rebound might suggest that the
mildest cases should not be treated. In the study by the French Cooperative
Group on Plasma Exchange in Guillain-Barré Syndrome, untreated mild
cases, which included some patients who would fall in to Medical Research
Council grade 3 in addition to grades 1 and 2, had a median time to the onset
of motor recovery of 8 days, compared with 4 days in those treated with plasmapheresis.
However, all the relapses occurred in the treatment group.4
This difference in latency of motor improvement was modest and both their
and our data suggest no difference in long-term sequelae between treated and
untreated patients with mild affection. Therefore, there seems to be no definitive
evidence that treatment is warranted in these patients.
There were no distinguishing clinical or electrophysiologic features
between our treated and untreated patients with mild GBS, nor were there important
differences between patients with mild GBS and those more severely affected
that would allow for the prediction of a persistently mild course. Given that
there is no reliable predictive factor that can be obtained from a single
visit, it may be advisable to hospitalize these patients for 2 to 3 days to
demonstrate a stable trend indicative of a mild course of GBS. Those whose
conditions are no worse at approximately 8 days are expected to remain in
the mild category. A tentative suggestion might be to wait until the eighth
day or so before deciding on treatment of patients who still are able to walk.
AUTHOR INFORMATION
Accepted for publication September 6, 2000.
From the Department of Neurology, St Elizabeth's Medical Center, Boston,
Mass. Dr Green is now with the Neuroscience Institute, The Queen's Medical
Center, Honolulu, Hawaii.
Reprints: Deborah M. Green, MD, Neuroscience Institute, The Queen's
Medical Center, 1301 Punchbowl St, Honolulu, HI 96813 (e-mail: dgreen{at}queens.org).
REFERENCES
| |
1. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet. 1978;2:750-753.
FULL TEXT
|
ISI
| PUBMED
2. Van Koningsveld R, Van Doorn PA, Schmitz PI, Ang CW, Van der Meché FGA. Mild forms of Guillain-Barré syndrome in an epidemiologic survey
in the Netherlands. Neurology. 2000;54:620-625.
FREE FULL TEXT
3. Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barré Syndrome. Philadelphia, Pa: FA Davis Co; 1991:87-89, 266.
4. The French Cooperative Group on Plasma Exchange in Guillain-Barré
Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol. 1997;41:298-306.
FULL TEXT
|
ISI
| PUBMED
5. Winer JB, Hughes RA, Osmond C. A prospective study of acute idiopathic neuropathy, I: clinical features
and their prognostic value. J Neurol Neurosurg Psychiatry. 1988;51:605-612.
ABSTRACT
6. Marshall J. The Landry-Guillain-Barré syndrome. Brain. 1963;86:55-66.
FREE FULL TEXT
7. Ravn H. The Landry-Guillain-Barré syndrome: a survey and a clinical
report of 127 cases. Acta Neurol Scand Suppl. 1967;43:1-64.
8. Loffel NB, Rossi LN, Mumenthaler M, Lutschg J, Ludin HP. The Landry-Guillain-Barré syndrome: complications, prognosis
and natural history in 123 cases. J Neurol Sci. 1977;33:71-79.
FULL TEXT
|
ISI
| PUBMED
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2001;58(7):1172-1174.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Economic cost of Guillain-Barre syndrome in the United States
Frenzen
Neurology 2008;71:21-27.
ABSTRACT
| FULL TEXT
Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barre Syndrome: A Randomized Trial
Korinthenberg et al.
Pediatrics 2005;116:8-14.
ABSTRACT
| FULL TEXT
Use of Cellular and Plasma Apheresis in the Critically Ill Patient: Part II: Clinical Indications and Applications
Linenberger and Price
J Intensive Care Med 2005;20:88-103.
ABSTRACT
Practice parameter: Immunotherapy for Guillain-Barre syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Latov and Hughes
Neurology 2004;62:1653-1654.
FULL TEXT
Differences in patterns of progression in demyelinating and axonal Guillain-Barre syndromes
Hiraga et al.
Neurology 2003;61:471-474.
ABSTRACT
| FULL TEXT
Infections and course of disease in mild forms of Guillain-Barre syndrome
Van Koningsveld et al.
Neurology 2002;58:610-614.
ABSTRACT
| FULL TEXT
Mild Guillain-Barre Syndrome: How Should It Be Managed?
JWatch Neurology 2001;2001:4-4.
FULL TEXT
|
